Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users.

AIDS. 1999 May 28;13(8):981-5. Unique Identifier : AIDSLINE MED/99297590
Alexander CS; Dong W; Schechter MT; O'Shaughnessy MV; Strathdee SA; Mo T; Montaner JS; Harrigan PR; BC Centre for Excellence in HIV/AIDS, St Paul's Hospital,; Vancouver, Canada.

Abstract: OBJECTIVES: This study examined the frequency of transmission of drug resistant HIV in the population of injecting drug users (IDU) in Vancouver, Canada during a period of particularly high virus transmission. DESIGN: All subjects enrolled in the Vancouver Injection Drug Users Study who seroconverted from HIV negative to positive status (n = 61) between December 1996 and February 1998 were eligible for analysis. The first seropositive sample from 57 individuals with plasma samples available was analyzed for resistance to antiretroviral agents by population based sequencing of the HIV protease and reverse transcriptase genes. METHODS: Plasma viral RNA was extracted and the viral reverse transcriptase and protease regions were amplified by nested reverse transcription-PCR. The presence of mutations associated with antiretroviral drug resistance was assessed by automated sequence analysis. RESULTS: Protease and reverse transcriptase sequences were successfully obtained from the 57 recent seroconverters. No cases of transmission of variants associated with significant resistance to protease inhibitors or nucleoside and non-nucleosides reverse transcriptase inhibitors were detected. CONCLUSION: The frequency of transmission of drug resistant HIV amongst these recently infected IDU is extremely low, with no protease or reverse transcriptase inhibitor resistant strains detected soon after seroconversion. The data provide no rationale for withholding treatment from this already marginalized population.

Keywords: JOURNAL ARTICLE Anti-HIV Agents/*PHARMACOLOGY Base Sequence Canada Disease Outbreaks Drug Resistance, Microbial/GENETICS DNA, Viral/ANALYSIS Human HIV Infections/*COMPLICATIONS/EPIDEMIOLOGY/TRANSMISSION/*VIROLOGY HIV Protease/GENETICS HIV-1/*DRUG EFFECTS/*GENETICS HIV-1 Reverse Transcriptase/GENETICS Mutation Reverse Transcriptase Polymerase Chain Reaction RNA, Viral/BLOOD Sequence Analysis, DNA Substance Abuse, Intravenous/*COMPLICATIONS Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Viral Load
991130
A99B1108

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .